Financial reports
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
10 May 22
10-K
2021 FY
Annual report
1 Mar 22
10-Q
2021 Q3
Quarterly report
9 Nov 21
10-Q
2021 Q2
Quarterly report
9 Aug 21
10-Q
2021 Q1
Quarterly report
6 May 21
10-K
2020 FY
Annual report
23 Feb 21
10-Q
2020 Q3
Quarterly report
6 Nov 20
10-Q
2020 Q2
Quarterly report
4 Aug 20
10-Q
2020 Q1
Quarterly report
4 May 20
Current reports
8-K
Termination of a Material Definitive Agreement
12 Aug 22
8-K
Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update
9 Aug 22
8-K
Ipsen to acquire Epizyme, expanding its portfolio in oncology
27 Jun 22
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
24 May 22
8-K
Departure of Directors or Certain Officers
19 May 22
8-K
Epizyme Reports First Quarter 2022 Financial Results and Provides Business Update
10 May 22
8-K
Departure of Directors or Certain Officers
6 Apr 22
8-K
Epizyme Announces Executive Appointment and Provides Tazemetostat Clinical Update
15 Mar 22
8-K
Epizyme Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
1 Mar 22
8-K
Entry into a Material Definitive Agreement
27 Jan 22
Registration and prospectus
15-12G
Securities registration termination
23 Aug 22
POS AM
Prospectus update (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
13 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Aug 22
S-8 POS
Registration of securities for employees (post-effective amendment)
12 Aug 22
Proxies
DEFA14A
Additional proxy soliciting materials
30 Mar 22
DEF 14A
Definitive proxy
30 Mar 22
PRE 14A
Preliminary proxy
17 Mar 22
DEFA14A
Additional proxy soliciting materials
29 Apr 21
DEF 14A
Definitive proxy
29 Apr 21
PRE 14A
Preliminary proxy
15 Apr 21
DEFA14A
Additional proxy soliciting materials
17 Apr 20
DEF 14A
Definitive proxy
17 Apr 20
PRE 14A
Preliminary proxy
6 Apr 20
DEFA14A
Additional proxy soliciting materials
18 Apr 19
Other
EFFECT
Notice of effectiveness
17 Aug 22
EFFECT
Notice of effectiveness
17 Aug 22
EFFECT
Notice of effectiveness
17 Aug 22
CT ORDER
Confidential treatment order
3 May 22
CT ORDER
Confidential treatment order
14 Mar 22
EFFECT
Notice of effectiveness
30 Sep 21
CORRESP
Correspondence with SEC
27 Sep 21
UPLOAD
Letter from SEC
27 Sep 21
EFFECT
Notice of effectiveness
14 May 21
CORRESP
Correspondence with SEC
11 May 21
Ownership
SC 13G/A
Palo Alto Investors LP
14 Feb 23
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
8 Sep 22
4
Michael F Giordano
16 Aug 22
4
CARL GOLDFISCHER
16 Aug 22
4
Kevin T Conroy
16 Aug 22
4
Victoria Richon
16 Aug 22
4
DAVID M MOTT
16 Aug 22
4
ROY A BEVERIDGE,
16 Aug 22
4
Shefali Agarwal
16 Aug 22
4
Jerald Korn
16 Aug 22